Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

Abstract:

:The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same period. Median age was 45 years (range: 4-84). All had been initially misdiagnosed as malignant lymphoma (ML) and a median of 2.9 months (range: 1-6) elapsed between the misdiagnosis and the correct of MS, effectuated in our department. At that time, a bone marrow examination revealed a myelodysplastic condition in seven patients, an infiltration by blast cells >30% in two patients, and normal features in the other three. In the non-leukemic patients a median of 5 months (range: 2-44 months) elapsed between the diagnosis of MS and acute leukemia. In all, 10 patients received intensive treatment. A total of seven patients (70%) achieved MS complete remission (CR). Patients who presented isolated skin localization and received only radiotherapy, obtained a MS-CR, but subsequently developed AML. Only in patients who were treated within 4 months from the initial ML diagnosis we achieved complete remission of both MS and leukemia, whereas in patients who were treated after this time, we obtained a complete disappearance of MS without response at the bone-marrow level, irrespectively of the specific therapy regimen. Median survival time from MS diagnosis was 7 months (range: 1-49 months), and only one patient is still alive, 49 months after bone marrow transplantation. Our data stress the importance of an accurate and prompt identification of this rare form of AML, and suggest that, even in patients with isolated MS, the early administration of AML-like intensive chemotherapy followed by bone marrow transplantation might reduce the risk of subsequently developing systemic disease.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Breccia M,Mandelli F,Petti MC,D'Andrea M,Pescarmona E,Pileri SA,Carmosino I,Russo E,De Fabritiis P,Alimena G

doi

10.1016/j.leukres.2004.01.022

keywords:

subject

Has Abstract

pub_date

2004-11-01 00:00:00

pages

1165-9

issue

11

eissn

0145-2126

issn

1873-5835

pii

S0145212604001146

journal_volume

28

pub_type

杂志文章,评审
  • Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.

    abstract::Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effecti...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.05.018

    authors: Kim JH,Song M,Kang GH,Lee ER,Choi HY,Lee C,Kim JH,Kim Y,Koo BN,Cho SG

    更新日期:2012-09-01 00:00:00

  • Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.

    abstract:BACKGROUND/AIMS:Multiple myeloma (MM) is caused by proliferation of clonal plasma cells (cPCs) in bone marrow (BM), associated with numerical and functional defects in immune subsets. An impairment of B cell compartment is involved in onset/progression of the disease. METHODS:By flow cytometry, we studied distribution...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.08.008

    authors: Pojero F,Casuccio A,Giambanco C,Bulati M,Buffa S,Di Bassiano F,Gervasi F,Caruso C,Colonna Romano G

    更新日期:2016-10-01 00:00:00

  • Bone marrow and extramedullary variations of cell membrane antigen expression in childhood lymphoid neoplasias at relapse.

    abstract::To increase our knowledge of the pathogenesis of tumour recurrence, cell membrane phenotypes were determined on bone marrow and extramedullary tumour cells at diagnosis and at relapse in 24 children with lymphoid malignancies. There were 19 patients with acute lymphoblastic leukemia and five with non-Hodgkin's lymphom...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90058-3

    authors: Lauer S,Piaskowski V,Camitta B,Casper J

    更新日期:1982-01-01 00:00:00

  • Glycosylation interference on RhoA activation: focus on G-CSF.

    abstract::Glycosylation of cytokines appears to be responsible for several differences in their activity, and focusing on G-CSF, several divergences between the non-glycosylated G-CSF, Filgrastim, and the glycosylated G-CSF, Lenograstim, have been reported. To verify the role of G-CSF glycosylation in mediating these difference...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.05.027

    authors: Mattii L,Battolla B,Azzarà A,D'Urso G,Montali U,Petrini M

    更新日期:2011-02-01 00:00:00

  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

    abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2013.01.004

    authors: Adès L,Sekeres MA,Wolfromm A,Teichman ML,Tiu RV,Itzykson R,Maciejewski JP,Dreyfus F,List AF,Fenaux P,Komrokji RS

    更新日期:2013-06-01 00:00:00

  • Socioeconomic status and event free survival in pediatric acute lymphoblastic leukemia: a population-based cohort study.

    abstract::The impact of socioeconomic status (SES) upon childhood cancer outcomes has not been extensively examined. Our objective was to determine the association between SES and event-free survival (EFS) among children with acute lymphoblastic leukemia (ALL) diagnosed in Ontario, Canada from 1995-2011 (N=1541) using Cox propo...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.leukres.2014.08.017

    authors: Gupta S,Sutradhar R,Guttmann A,Sung L,Pole JD

    更新日期:2014-12-01 00:00:00

  • Cytogenetic studies in children with Down syndrome and acute leukemia.

    abstract::The frequency of chromosomal alterations was compared among four children groups: those with Down syndrome and acute leukemia (DS/AL), those with acute leukemia (AL), those with only Down syndrome (DS) and healthy children (NC). The frequency of acquired chromosome abnormalities was larger in the AL group, followed by...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.03.015

    authors: Valladares A,Palma-Padilla V,Mejía-Aranguré JM,Guevara-Yánez R,Lerma-Reyes A,Salamanca-Gómez F

    更新日期:2005-11-01 00:00:00

  • Evidence for the in vivo production of interleukin-3 in lethally irradiated mice transplanted with syngeneic murine splenocytes.

    abstract::We wish to demonstrate new evidence for the in vivo production of interleukin-3 (IL-3). Syngeneic murine splenocytes were transplanted into lethally irradiated mice. The spleen cells in these transplant mice spontaneously produced IL-3 in cultures, and IL-3-like activity was detected in the serum. Chronological change...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90138-0

    authors: Hirokawa M,Takatsu H,Chubachi A,Kudo K,Takahashi T,Yoshida K,Miura AB

    更新日期:1989-01-01 00:00:00

  • Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia.

    abstract::Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the ex...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2003.10.034

    authors: Sato N,Kishi K,Toba K,Watanabe K,Itoh H,Narita M,Takahashi M,Aizawa Y

    更新日期:2004-07-01 00:00:00

  • Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression.

    abstract::Deregulated myc, bcl-2 and/or TP53 gene expression is associated with non-Hodgkin's B cell lymphomas (B-NHLs). Emu-N-myc transgenic mice that misexpress N-myc protein and carry a non-disrupted bcl-2 gene develop indolent B cell lymphomas reminiscent of the B-NHL, follicular lymphoma. Tumors from mice with end-stage di...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00103-4

    authors: Samant SA,Sheppard RD

    更新日期:1999-10-01 00:00:00

  • Incorporation of nucleic acid and protein precursors in enriched populations of proliferating normal and leukemic cells.

    abstract::Nucleic acid and protein synthesis was determined in immature myeloid cells isolated from seven normal bone marrow samples and compared to blasts from nine patients with fullblown acute non-lymphocytic leukemia. Samples obtained from normal bone marrow contained a mean of 82% immature myeloid cells with 29.9% S-phase ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90098-4

    authors: Burghouts JT,Plas AM,Salden MH,Wessels HM

    更新日期:1982-01-01 00:00:00

  • CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.

    abstract::Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.01.014

    authors: Usvasalo A,Savola S,Räty R,Vettenranta K,Harila-Saari A,Koistinen P,Savolainen ER,Elonen E,Saarinen-Pihkala UM,Knuutila S

    更新日期:2008-08-01 00:00:00

  • Intracellular accumulation of cytosine arabinoside in murine normal and neoplastic lymphocytes following their exposure to sodium 2-mercaptoethanesulphonate.

    abstract::The effect of mesna on intracellular accumulation of cytosine arabinoside (Ara-C) in murine normal and neoplastic lymphocytes was studied. Simultaneous exposure of cells to mesna at concentrations ranging from 0.25 to 1.0 mM and 3H-Ara-C (40.0 nM) resulted in a strong inhibition of Ara-C uptake in normal lymphocytes. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90117-4

    authors: Jastrzebski Z,Czyzewska-Szafran H,Remiszewska M,Côte-Rozanes C

    更新日期:1993-09-01 00:00:00

  • Differentiation of isotope-labeled myeloid leukemia cells free in the peritoneal cavity of syngeneic mice.

    abstract::Ml cells were labeled in vitro with [3H]thymidine and injected into the peritoneal cavity of syngeneic mice. After several days the peritoneal cells were harvested and [3H]labeled cells were determined by autoradiography. The inoculated isotope-labeled Ml cells differentiated in the peritoneal cavity and lipopolysacch...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90050-9

    authors: Honma Y,Hayashi M,Kasukabe T,Hozumi M

    更新日期:1982-01-01 00:00:00

  • A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

    abstract::Anti-MY9 is an IgG2b murine monoclonal antibody selected for reactivity with immature normal human myeloid cells. The MY9 antigen is expressed by blasts, promyelocytes and myelocytes in the bone marrow, and by monocytes in the peripheral blood. Erythrocytes, lymphocytes and platelets are MY9 negative. All myeloid colo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90001-8

    authors: Griffin JD,Linch D,Sabbath K,Larcom P,Schlossman SF

    更新日期:1984-01-01 00:00:00

  • Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

    abstract::Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-pla...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.10.004

    authors: Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

    更新日期:2009-06-01 00:00:00

  • Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization.

    abstract::Dimethyl sulfoxide (DMSO) is a widely used prototypical chemical inducer of cell differentiation. In the present study, the effects of DMSO on susceptibility of human myeloid leukemia U937 cells towards ligation of distinct death receptors (DRs) were investigated. DMSO sensitized cells towards induction of apoptosis b...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.05.016

    authors: Vondrácek J,Soucek K,Sheard MA,Chramostová K,Andrysík Z,Hofmanová J,Kozubík A

    更新日期:2006-01-01 00:00:00

  • Quality of life of patients with acute myeloid leukaemia.

    abstract::In a prospective study of 27 patients with acute myeloid leukaemia (AML) quality of life was studied using three different instruments, Life Ingredient Profile, Karnofsky Performance Scale and Vitagram. The course of the disease was followed during the induction period, remission, relapse and in the terminal phase. We...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90028-0

    authors: Stalfelt AM

    更新日期:1994-04-01 00:00:00

  • Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.

    abstract::We have earlier shown that VP-16 combined with Cyclosporin A (CsA) produces tumor specific immunity to L1210 leukemia in BDF/1 mice [Slater LM, Sweet P, Stupecky M, Reynolds JT. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD(8) T-lymphocytes, Clin Immunol Immunopathol 1995;7...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00105-9

    authors: Slater LM,Stupecky M,Sweet P,Osann KE

    更新日期:2002-02-01 00:00:00

  • Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events.

    abstract:BACKGROUND:Chromosomal aberrations at the ETV6 gene locus on 12p13.2 are common in bone marrow samples involved by blastic plasmacytoid dendritic cell neoplasm (BPDCN). However, their pathogenic role, incidence in cutaneous BPDCN lesions, and clinical significance have not been assessed systematically. RESULTS:The stu...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2018.09.006

    authors: Tang Z,Li Y,Wang W,Yin CC,Tang G,Aung PP,Hu S,Lu X,Toruner GA,Medeiros LJ,Khoury JD

    更新日期:2018-10-01 00:00:00

  • Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.

    abstract::Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.02.002

    authors: Cividin M,Ayrault O,Sorel N,Séité P,Brizard F,Blanchet O,Mahon FX,Guilhot F,Larsen C,Chomel JC,Brizard A

    更新日期:2006-10-01 00:00:00

  • The GNAS1 gene in myelodysplastic syndromes (MDS).

    abstract::GNAS1 gene is located at the long arm of chromosome 20 (q13.32). GNAS1 gene deletion has never been investigated in MDS. A GNAS1 activating mutation (R201) was recently found in MDS. We applied FISH and DHPLC plus sequencing to investigate GNAS1 gene in MDS cases with and without del(20q) at karyotype. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2014.03.017

    authors: Di Giacomo D,Lema Fernandez AG,Pierini T,Crescenzi B,Brandimarte L,Matteucci C,Testoni N,Mecucci C

    更新日期:2014-07-01 00:00:00

  • Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.

    abstract::In this case-control study, interview data on smoking habits were available for 179 de novo cases (116 with cytogenetic data) of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Smoking habits were compared with a pooled set of population controls and hospital controls (diagnosed with malignant melanom...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.10.009

    authors: Björk J,Johansson B,Broberg K,Albin M

    更新日期:2009-06-01 00:00:00

  • Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

    abstract::The aim of the study was to investigate the expression of MIP-1 alpha and sclerostin in bone marrow of patients with multiple myeloma (MM), the possible association of the sclerostin and MIP-1 alpha with MBD and the clinical characteristics. 53 patients (29 M, 24 F), median age 64 years was studied. MIP-1 alpha, scler...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2014.02.010

    authors: Wang XT,He YC,Zhou SY,Jiang JZ,Huang YM,Liang YZ,Lai YR

    更新日期:2014-05-01 00:00:00

  • Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias.

    abstract::Checkpoint genes code for a family of proteins which sense DNA damage in eukaryotic cells. They play an important role in the control of the cell cycle. The human CHK2 is a homolog of the yeast G(2) checkpoint kinases known as CDS1 and RAD53. The CHK2 may be a tumor suppressor gene because it was found to be mutated i...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(00)00130-2

    authors: Hofmann WK,Miller CW,Tsukasaki K,Tavor S,Ikezoe T,Hoelzer D,Takeuchi S,Koeffler HP

    更新日期:2001-04-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract::To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.11.008

    authors: Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期:2010-08-01 00:00:00

  • Reversine triggers mitotic catastrophe and apoptosis in K562 cells.

    abstract::Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm of the hematopoietic stem cell characterized by presence of the oncoprotein BCR-ABL1, which have constitutive tyrosine kinase activity. BCR-ABL1 activation induces aurora kinase A (AURKA) and aurora kinase B (AURKB) expression, which are serine-thr...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.06.011

    authors: Rodrigues Alves AP,Machado-Neto JA,Scheucher PS,Paiva HH,Simões BP,Rego EM,Traina F

    更新日期:2016-09-01 00:00:00

  • Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

    abstract::This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.06.030

    authors: Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

    更新日期:2011-12-01 00:00:00

  • Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.

    abstract::We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma. Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed. The median follow-up duration w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.06.012

    authors: Ali A,Sayed H,Farrag A,El-Sayed M

    更新日期:2010-11-01 00:00:00

  • Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.

    abstract::FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.11.006

    authors: Kang HJ,Hong SH,Kim IH,Park BK,Han KS,Cho HI,Shin HY,Ahn HS

    更新日期:2005-06-01 00:00:00